Document Detail

Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
MedLine Citation:
PMID:  23320916     Owner:  NLM     Status:  Publisher    
BACKGROUND: Chronic plaque psoriasis is frequently associated to metabolic disorders including obesity. Anti-TNF-alpha treatments can induce body weight increase in patients with psoriasis. Information on the effect of ustekinumab on the body weight is not available. OBJECTIVE: To investigate whether therapy with ustekinumab is associated with changes in body mass index (BMI) in patients with chronic plaque psoriasis. METHODS: A prospective, multi-center study comparing the changes in BMI in two closed cohorts of psoriatic patients during 7-month treatment with ustekinumab (N=79) or infliximab (N=83). RESULTS: Patients treated for 7 months with infliximab showed a significant (p< 0.001) increase in BMI (2.1% ± 4.5, mean ± SD) and body weight (+2.5 ± 3.3 kg) compared to patients treated with ustekinumab (0.1% ± 3.3; 0.6 Kg ± 1.1). 45% of patients treated with infliximab had a BMI increase greater 2% compared to only 11% of those receiving ustekinumab (p=0.01). At the multivariate analysis, any other clinical parameters predicted the BMI increase except for the use of infliximab. At month 7, 96% of patients treated with infliximab and 82% of patients treated with ustekinumab achieved at least a 50% improvement from their baseline PASI (PASI 50) and 69% of the infliximab group compared to 58% of ustekinumab group achieved at least a 75% improvement (PASI 75). There was no difference in the proportion of PASI 50 and PASI 75 responders between the two groups. CONCLUSIONS: In contrast to infliximab, ustekinumab does not increase BMI in patients with chronic plaque psoriasis. This difference could be taken into account in the selection of biologics for treating patients with psoriasis.
P Gisondi; A Conti; G Galdo; S Piaserico; C De Simone; G Girolomoni
Related Documents :
24154146 - Correlation of nutritional status using subjective global assessment (sga) on pulmonary...
24525446 - Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide le...
23541686 - Development of a standardized elisa for the determination of autoantibodies against hum...
24954116 - Treatment by testicular sperm extraction and intracytoplasmic sperm injection of 65 azo...
12361896 - Randomised, placebo controlled, double blind study of alfuzosin sr in patients undergoi...
12064856 - New onset systemic lupus erythematosus with pheochromocytoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-16
Journal Detail:
Title:  The British journal of dermatology     Volume:  -     ISSN:  1365-2133     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
©The Authors BJD © 2013 British Association of Dermatologists.
Section of Dermatology, Department of Medicine, University of Verona.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blood transfusions and the subsequent risk of cancers in the United States elderly.
Next Document:  Optical and Time-Resolved Electron Paramagnetic Resonance Studies of the Excited States of a UV-B Ab...